{"protocolSection":{"identificationModule":{"nctId":"NCT01371721","orgStudyIdInfo":{"id":"B2061031"},"secondaryIdInfos":[{"id":"3151A6-3357","type":"OTHER","domain":"Alias Study Number"},{"id":"2008-002064-34","type":"EUDRACT_NUMBER"},{"id":"2008","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2008"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD","officialTitle":"A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder"},"statusModule":{"statusVerifiedDate":"2016-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2012-02"},"primaryCompletionDateStruct":{"date":"2015-10","type":"ACTUAL"},"completionDateStruct":{"date":"2015-10","type":"ACTUAL"},"studyFirstSubmitDate":"2011-06-09","studyFirstSubmitQcDate":"2011-06-10","studyFirstPostDateStruct":{"date":"2011-06-13","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-04-19","resultsFirstSubmitQcDate":"2016-12-16","resultsFirstPostDateStruct":{"date":"2017-02-08","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-12-16","lastUpdatePostDateStruct":{"date":"2017-02-08","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD)."},"conditionsModule":{"conditions":["Major Depressive Disorder"],"keywords":["Major Depressive Disorder","MDD","Depression"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":269,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Desvenlafaxine Succinate Sustained-Release","type":"EXPERIMENTAL","interventionNames":["Drug: DVS SR"]}],"interventions":[{"type":"DRUG","name":"DVS SR","description":"Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.","armGroupLabels":["Desvenlafaxine Succinate Sustained-Release"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Experiencing a Treatment Emergent Adverse Event","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study"}],"secondaryOutcomes":[{"measure":"Change From Baseline at Week 26 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score Based on Observed Cases","description":"Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Adjusted mean presented.","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study"},{"measure":"Change From Baseline at Week 26 in the Clinical Global Impression of Severity (CGI-S) Score Based on Observed Cases","description":"A 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. Change: score at observation minus score at baseline. Adjusted mean presented.","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study"},{"measure":"Percentage of Participants With a Clinical Global Impression, Improvement (CGI-I) Response Defined as a Score of 'Very Much Improved' or 'Much Improved' at Week 26","description":"A 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Higher score = more affected.","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study"},{"measure":"Percentage of Participants With Remission as Determined by a CDRS-R Score of ≤28 at Week 26 Based on Observed Cases","description":"Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Adjusted mean presented.","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study"},{"measure":"Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Week 26 Based on Observed Cases","description":"A 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed study B2061014 and who in the investigator's opinion would benefit from long term treatment with DVS SR\n* Willingness and ability to comply with scheduled visits, treatment plan and procedures\n\nExclusion Criteria:\n\n* Subject requires precaution against suicide\n* Subject not in a generally healthy condition","healthyVolunteers":false,"sex":"ALL","minimumAge":"7 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Harmonex Neuroscience Research, Inc.","city":"Dothan","state":"Alabama","zip":"36303","country":"United States","geoPoint":{"lat":31.22323,"lon":-85.39049}},{"facility":"Dedicated Clinical Research","city":"Goodyear","state":"Arizona","zip":"85395","country":"United States","geoPoint":{"lat":33.43532,"lon":-112.35821}},{"facility":"University of Arizona Clinical and Translational Science Center (CATS)","city":"Tucson","state":"Arizona","zip":"85724","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"University of Arizona College of Medicine Dept of Psychiatry","city":"Tucson","state":"Arizona","zip":"85724","country":"United States","geoPoint":{"lat":32.22174,"lon":-110.92648}},{"facility":"Arkansas Psychiatric Clinic Clinical Research Trials, P.A.","city":"Little Rock","state":"Arkansas","zip":"72211","country":"United States","geoPoint":{"lat":34.74648,"lon":-92.28959}},{"facility":"ATP Clinical Research, Incorporated","city":"Costa Mesa","state":"California","zip":"92626","country":"United States","geoPoint":{"lat":33.64113,"lon":-117.91867}},{"facility":"Behavioral Research Specialists, LLC","city":"Glendale","state":"California","zip":"91206","country":"United States","geoPoint":{"lat":34.14251,"lon":-118.25508}},{"facility":"Synergy Clinical Research Center","city":"National City","state":"California","zip":"91950","country":"United States","geoPoint":{"lat":32.67811,"lon":-117.0992}},{"facility":"Neuropsychiatric Research Center of Orange County","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"Pacific Clinical Research Medical Group","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"Elite Clinical Trials, Incorporated","city":"Wildomar","state":"California","zip":"92595","country":"United States","geoPoint":{"lat":33.59891,"lon":-117.28004}},{"facility":"Children's Hospital Colorado","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"Amedica Research Institute, Incorporated","city":"Hialeah","state":"Florida","zip":"33013","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"Clinical Neuroscience Solutions, Inc.","city":"Orlando","state":"Florida","zip":"32801","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Kolin Research Group","city":"Winter Park","state":"Florida","zip":"32789-3747","country":"United States","geoPoint":{"lat":28.6,"lon":-81.33924}},{"facility":"Atlanta Center for Medical Research","city":"Atlanta","state":"Georgia","zip":"30331","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Institute for Behavioral Medicine, LLC","city":"Smyrna","state":"Georgia","zip":"30080","country":"United States","geoPoint":{"lat":33.88399,"lon":-84.51438}},{"facility":"Psychiatric Associates","city":"Overland Park","state":"Kansas","zip":"66211","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"Lake Charles Clinical Trials,","city":"Lake Charles","state":"Louisiana","zip":"70629","country":"United States","geoPoint":{"lat":30.21309,"lon":-93.2044}},{"facility":"Precise Research Centers","city":"Flowood","state":"Mississippi","zip":"39232","country":"United States","geoPoint":{"lat":32.30959,"lon":-90.13898}},{"facility":"St. Charles Psychiatric Associates - Midwest Research Group","city":"Saint Charles","state":"Missouri","zip":"63303","country":"United States","geoPoint":{"lat":38.78394,"lon":-90.48123}},{"facility":"Center for Psychiatry and Behavioral Medicine, Incorporated","city":"Las Vegas","state":"Nevada","zip":"89128","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"North Star Medical Research, LLC","city":"Middleburg Heights","state":"Ohio","zip":"44130","country":"United States","geoPoint":{"lat":41.36144,"lon":-81.81291}},{"facility":"IPS Research Company","city":"Oklahoma City","state":"Oklahoma","zip":"73103","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Cutting Edge Research Group","city":"Oklahoma City","state":"Oklahoma","zip":"73116","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Paradigm Research Professionals, LLC","city":"Oklahoma City","state":"Oklahoma","zip":"73118","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Summit Research Network (Oregon), Incorporated","city":"Portland","state":"Oregon","zip":"97210","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Clinical Neuroscience Solutions, Inc.","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Focus & Balance, LLC","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Grayline Clinical Drug Trials","city":"Witchita Falls","state":"Texas","zip":"76309","country":"United States"},{"facility":"Northwest Clinical Research Center","city":"Bellevue","state":"Washington","zip":"98007","country":"United States","geoPoint":{"lat":47.61038,"lon":-122.20068}},{"facility":"Summit Research Network (Seattle) LLC","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"Rogers Center for Research and Training, Incorporated","city":"Milwaukee","state":"Wisconsin","zip":"53227","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}},{"facility":"Hospital Aranda de la Parra, S.A. de C.V.","city":"León","state":"Guanajuato","zip":"37000","country":"Mexico","geoPoint":{"lat":21.12183,"lon":-101.68253}},{"facility":"CIT-Neuropsique, S.C.","city":"Monterrey","state":"Nuevo León","zip":"64010","country":"Mexico","geoPoint":{"lat":25.68435,"lon":-100.31721}}]},"referencesModule":{"references":[{"pmid":"30419989","type":"DERIVED","citation":"Atkinson S, Thurman L, Ramaker S, Buckley G, Jones SR, England R, Wajsbrot D. Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials. CNS Spectr. 2019 Oct;24(5):496-506. doi: 10.1017/S1092852918001128."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2061031&StudyName=A%206-Month%20Open-Label%20Extension%20Study%20to%20the%20B2061014%20Study%20to%20Evaluate%20the%20Safety%2C%20Tolerability%20and%20Efficacy%20of%20DVS%20SR%20in%20the%20Trea"}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Participants who completed the 8-week, double-blind treatment phase of Desvenlafaxine Succinate Sustained Release (DVS SR B2061014 NCT01372150) and completed the 1-week transition phase (week 9) of the short-term study were eligible to participate in this study (DVS SR B2061031).","groups":[{"id":"FG000","title":"Placebo / DVS SR","description":"Placebo in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"FG001","title":"Fluoxetine / DVS SR","description":"Fluoxetine 20 mg in previous study B2061014 /DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"FG002","title":"Desvenlafaxine Succinate Sustained Release / DVS SR","description":"DVS SR weight based (25 mg, 35 mg, 50 mg) in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"88"},{"groupId":"FG001","numSubjects":"89"},{"groupId":"FG002","numSubjects":"92"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"87"},{"groupId":"FG001","numSubjects":"89"},{"groupId":"FG002","numSubjects":"92"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"59"},{"groupId":"FG001","numSubjects":"65"},{"groupId":"FG002","numSubjects":"62"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"30"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"5"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"11"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Randomized but not treated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population - included all randomized participants who received at least 1 dose of study drug.","groups":[{"id":"BG000","title":"Placebo / DVS SR","description":"Placebo in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"BG001","title":"Fluoxetine / DVS SR","description":"Fluoxetine 20 mg in previous study B2061014 /DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"BG002","title":"Desvenlafaxine Succinate Sustained Release / DVS SR","description":"DVS SR weight based (25 mg, 35 mg, 50 mg) in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"89"},{"groupId":"BG002","value":"92"},{"groupId":"BG003","value":"268"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12.5","spread":"2.90"},{"groupId":"BG001","value":"12.4","spread":"3.01"},{"groupId":"BG002","value":"12.8","spread":"3.14"},{"groupId":"BG003","value":"12.6","spread":"3.01"}]}]}]},{"title":"Gender","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"49"},{"groupId":"BG003","value":"135"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"133"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"SECONDARY","title":"Change From Baseline at Week 26 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score Based on Observed Cases","description":"Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Adjusted mean presented.","populationDescription":"ITT-included all randomized participants who had a baseline (of study B2061031) CDRS-R evaluation (Week 9 of study B2061014) took at least 1 dose of study drug and had at least 1 CDRS-R evaluation after the first dose of study drug in the B2061031 study period.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a Scale","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study","groups":[{"id":"OG000","title":"Placebo / DVS SR","description":"Placebo in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG001","title":"Fluoxetine / DVS SR","description":"Fluoxetine 20 mg in previous study B2061014 /DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG002","title":"Desvenlafaxine Succinate Sustained Release / DVS SR","description":"DVS SR weight based (25 mg, 35 mg, 50 mg) in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG003","title":"Combination","description":"Combination of 3 groups from previous study B2061014 who received DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"172"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.55","spread":"10.80"},{"groupId":"OG001","value":"-6.41","spread":"11.50"},{"groupId":"OG002","value":"-5.32","spread":"7.29"},{"groupId":"OG003","value":"-5.78","spread":"10.03"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline at Week 26 in the Clinical Global Impression of Severity (CGI-S) Score Based on Observed Cases","description":"A 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. Change: score at observation minus score at baseline. Adjusted mean presented.","populationDescription":"ITT-included all randomized participants who had a baseline (of study B2061031) CDRS-R evaluation (Week 9 of study B2061014) took at least 1 dose of study drug and had at least 1 CDRS-R evaluation after the first dose of study drug in the B2061031 study period.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a Scale","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study","groups":[{"id":"OG000","title":"Placebo / DVS SR","description":"Placebo in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG001","title":"Fluoxetine / DVS SR","description":"Fluoxetine 20 mg in previous study B2061014 /DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG002","title":"Desvenlafaxine Succinate Sustained Release / DVS SR","description":"DVS SR weight based (25 mg, 35 mg, 50 mg) in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG003","title":"Combination","description":"Combination of 3 groups from previous study B2061014 who received DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"172"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"1.23"},{"groupId":"OG001","value":"-0.77","spread":"1.16"},{"groupId":"OG002","value":"-0.82","spread":"0.92"},{"groupId":"OG003","value":"-0.79","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Clinical Global Impression, Improvement (CGI-I) Response Defined as a Score of 'Very Much Improved' or 'Much Improved' at Week 26","description":"A 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Higher score = more affected.","populationDescription":"ITT-included all randomized participants who had a baseline (of study B2061031) CDRS-R evaluation (Week 9 of study B2061014) took at least 1 dose of study drug and had at least 1 CDRS-R evaluation after the first dose of study drug in the B2061031 study period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study","groups":[{"id":"OG000","title":"Placebo / DVS SR","description":"Placebo in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG001","title":"Fluoxetine / DVS SR","description":"Fluoxetine 20 mg in previous study B2061014 /DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG002","title":"Desvenlafaxine Succinate Sustained Release / DVS SR","description":"DVS SR weight based (25 mg, 35 mg, 50 mg) in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG003","title":"Combination","description":"Combination of 3 groups from previous study B2061014 who received DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"172"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9"},{"groupId":"OG001","value":"93.4"},{"groupId":"OG002","value":"92.9"},{"groupId":"OG003","value":"92.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Remission as Determined by a CDRS-R Score of ≤28 at Week 26 Based on Observed Cases","description":"Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Adjusted mean presented.","populationDescription":"ITT-included all randomized participants who had a baseline (of study B2061031) CDRS-R evaluation (Week 9 of study B2061014) took at least 1 dose of study drug and had at least 1 CDRS-R evaluation after the first dose of study drug in the B2061031 study period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study","groups":[{"id":"OG000","title":"Placebo / DVS SR","description":"Placebo in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG001","title":"Fluoxetine / DVS SR","description":"Fluoxetine 20 mg in previous study B2061014 /DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG002","title":"Desvenlafaxine Succinate Sustained Release / DVS SR","description":"DVS SR weight based (25 mg, 35 mg, 50 mg) in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG003","title":"Combination","description":"Combination of 3 groups from previous study B2061014 who received DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"172"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5"},{"groupId":"OG001","value":"78.7"},{"groupId":"OG002","value":"73.2"},{"groupId":"OG003","value":"75.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing a Treatment Emergent Adverse Event","populationDescription":"Safety Population-includes all treatment-assigned participants who took at least one dose of investigational product in the period of study B2061031.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study","groups":[{"id":"OG000","title":"Placebo / DVS SR","description":"Placebo in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG001","title":"Fluoxetine / DVS SR","description":"Fluoxetine 20 mg in previous study B2061014 /DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG002","title":"Desvenlafaxine Succinate Sustained Release / DVS SR","description":"DVS SR weight based (25 mg, 35 mg, 50 mg) in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG003","title":"Combination","description":"Combination of 3 groups from previous study B2061014 who received DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"92"},{"groupId":"OG003","value":"268"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1"},{"groupId":"OG001","value":"75.3"},{"groupId":"OG002","value":"73.9"},{"groupId":"OG003","value":"73.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Week 26 Based on Observed Cases","description":"A 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.","populationDescription":"ITT-included all randomized participants who had a baseline (of study B2061031) CDRS-R evaluation (Week 9 of study B2061014) took at least 1 dose of study drug and had at least 1 CDRS-R evaluation after the first dose of study drug in the B2061031 study period.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study","groups":[{"id":"OG000","title":"Placebo / DVS SR","description":"Placebo in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG001","title":"Fluoxetine / DVS SR","description":"Fluoxetine 20 mg in previous study B2061014 /DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG002","title":"Desvenlafaxine Succinate Sustained Release / DVS SR","description":"DVS SR weight based (25 mg, 35 mg, 50 mg) in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"},{"id":"OG003","title":"Combination","description":"Combination of 3 groups from previous study B2061014 who received DVS SR flexible dose 20 mg - 50 mg in extension study B2061031"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"56"},{"groupId":"OG003","value":"172"}]}],"classes":[{"title":"Very Much Improved","categories":[{"measurements":[{"groupId":"OG000","value":"63.6"},{"groupId":"OG001","value":"63.9"},{"groupId":"OG002","value":"57.1"},{"groupId":"OG003","value":"61.6"}]}]},{"title":"Much Improved","categories":[{"measurements":[{"groupId":"OG000","value":"27.3"},{"groupId":"OG001","value":"29.5"},{"groupId":"OG002","value":"35.7"},{"groupId":"OG003","value":"30.8"}]}]},{"title":"Minimally Improved","categories":[{"measurements":[{"groupId":"OG000","value":"3.6"},{"groupId":"OG001","value":"3.3"},{"groupId":"OG002","value":"5.4"},{"groupId":"OG003","value":"4.1"}]}]},{"title":"No Change","categories":[{"measurements":[{"groupId":"OG000","value":"3.6"},{"groupId":"OG001","value":"1.6"},{"groupId":"OG002","value":"1.8"},{"groupId":"OG003","value":"2.3"}]}]},{"title":"Minimally Worse","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.6"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.6"}]}]},{"title":"Much Worse","categories":[{"measurements":[{"groupId":"OG000","value":"1.8"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.6"}]}]},{"title":"Very Much Worse","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"3","timeFrame":"Adverse events (AEs) recorded from informed consent and assent through Week 30 and Serious Adverse events (SAEs) collected through Week 32 visit. Participants discontinuing prior to Week 28 visit, AEs collected for 14 days and SAEs for 28 days.","description":"Same event may appear as both an AE and an SAE.Data presented are distinct events.Aneven may be categorized as serious in 1 participant and non-serious in another or 1 participant may have experienced both a serious and non-serious event during study.Safety population included all randomized participants receiving at least 1 dose of study drug","eventGroups":[{"id":"EG000","title":"Placebo / DVS SR","description":"Placebo in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031","seriousNumAffected":5,"seriousNumAtRisk":87,"otherNumAffected":47,"otherNumAtRisk":87},{"id":"EG001","title":"Fluoxetine / DVS SR","description":"Fluoxetine 20 mg in previous study B2061014 /DVS SR flexible dose 20 mg - 50 mg in extension study B2061031","seriousNumAffected":2,"seriousNumAtRisk":89,"otherNumAffected":61,"otherNumAtRisk":89},{"id":"EG002","title":"Desvenlafaxine Succinate Sustained Release / DVS SR","description":"DVS SR weight based (25 mg, 35 mg, 50 mg) in previous study B2061014/DVS SR flexible dose 20 mg - 50 mg in extension study B2061031","seriousNumAffected":3,"seriousNumAtRisk":92,"otherNumAffected":62,"otherNumAtRisk":92},{"id":"EG003","title":"Combination","description":"Combination of 3 groups from previous study B2061014 who received DVS SR flexible dose 20 mg - 50 mg in extension study B2061031","seriousNumAffected":10,"seriousNumAtRisk":268,"otherNumAffected":170,"otherNumAtRisk":268}],"seriousEvents":[{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":87},{"groupId":"EG001","numAffected":0,"numAtRisk":89},{"groupId":"EG002","numAffected":1,"numAtRisk":92},{"groupId":"EG003","numAffected":1,"numAtRisk":268}]},{"term":"Aggression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":87},{"groupId":"EG001","numAffected":0,"numAtRisk":89},{"groupId":"EG002","numAffected":0,"numAtRisk":92},{"groupId":"EG003","numAffected":1,"numAtRisk":268}]},{"term":"Frustration","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":87},{"groupId":"EG001","numAffected":0,"numAtRisk":89},{"groupId":"EG002","numAffected":0,"numAtRisk":92},{"groupId":"EG003","numAffected":1,"numAtRisk":268}]},{"term":"Hallucination, auditory","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":87},{"groupId":"EG001","numAffected":0,"numAtRisk":89},{"groupId":"EG002","numAffected":0,"numAtRisk":92},{"groupId":"EG003","numAffected":1,"numAtRisk":268}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":87},{"groupId":"EG001","numAffected":0,"numAtRisk":89},{"groupId":"EG002","numAffected":0,"numAtRisk":92},{"groupId":"EG003","numAffected":1,"numAtRisk":268}]},{"term":"Self injurious behaviour","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":87},{"groupId":"EG001","numAffected":0,"numAtRisk":89},{"groupId":"EG002","numAffected":0,"numAtRisk":92},{"groupId":"EG003","numAffected":1,"numAtRisk":268}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":87},{"groupId":"EG001","numAffected":1,"numAtRisk":89},{"groupId":"EG002","numAffected":1,"numAtRisk":92},{"groupId":"EG003","numAffected":5,"numAtRisk":268}]},{"term":"Ovarian cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":87},{"groupId":"EG001","numAffected":0,"numAtRisk":89},{"groupId":"EG002","numAffected":1,"numAtRisk":92},{"groupId":"EG003","numAffected":1,"numAtRisk":268}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":87},{"groupId":"EG001","numAffected":1,"numAtRisk":89},{"groupId":"EG002","numAffected":0,"numAtRisk":92},{"groupId":"EG003","numAffected":1,"numAtRisk":268}]}],"otherEvents":[{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":9,"numAtRisk":268}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":87},{"groupId":"EG001","numAffected":8,"numAtRisk":89},{"groupId":"EG002","numAffected":7,"numAtRisk":92},{"groupId":"EG003","numAffected":22,"numAtRisk":268}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":1,"numAtRisk":92},{"groupId":"EG003","numAffected":6,"numAtRisk":268}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":87},{"groupId":"EG001","numAffected":5,"numAtRisk":89},{"groupId":"EG002","numAffected":2,"numAtRisk":92},{"groupId":"EG003","numAffected":10,"numAtRisk":268}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":87},{"groupId":"EG001","numAffected":0,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":5,"numAtRisk":268}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":87},{"groupId":"EG001","numAffected":1,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":4,"numAtRisk":268}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":87},{"groupId":"EG001","numAffected":14,"numAtRisk":89},{"groupId":"EG002","numAffected":8,"numAtRisk":92},{"groupId":"EG003","numAffected":31,"numAtRisk":268}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":87},{"groupId":"EG001","numAffected":9,"numAtRisk":89},{"groupId":"EG002","numAffected":6,"numAtRisk":92},{"groupId":"EG003","numAffected":20,"numAtRisk":268}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":8,"numAtRisk":268}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":87},{"groupId":"EG001","numAffected":1,"numAtRisk":89},{"groupId":"EG002","numAffected":4,"numAtRisk":92},{"groupId":"EG003","numAffected":5,"numAtRisk":268}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":2,"numAtRisk":92},{"groupId":"EG003","numAffected":7,"numAtRisk":268}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":5,"numAtRisk":92},{"groupId":"EG003","numAffected":12,"numAtRisk":268}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":87},{"groupId":"EG001","numAffected":1,"numAtRisk":89},{"groupId":"EG002","numAffected":1,"numAtRisk":92},{"groupId":"EG003","numAffected":7,"numAtRisk":268}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":87},{"groupId":"EG001","numAffected":4,"numAtRisk":89},{"groupId":"EG002","numAffected":6,"numAtRisk":92},{"groupId":"EG003","numAffected":21,"numAtRisk":268}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":87},{"groupId":"EG001","numAffected":2,"numAtRisk":89},{"groupId":"EG002","numAffected":4,"numAtRisk":92},{"groupId":"EG003","numAffected":7,"numAtRisk":268}]},{"term":"Pharyngitis streptococcal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":87},{"groupId":"EG001","numAffected":2,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":7,"numAtRisk":268}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":8,"numAtRisk":268}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":87},{"groupId":"EG001","numAffected":9,"numAtRisk":89},{"groupId":"EG002","numAffected":8,"numAtRisk":92},{"groupId":"EG003","numAffected":24,"numAtRisk":268}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":1,"numAtRisk":92},{"groupId":"EG003","numAffected":4,"numAtRisk":268}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":87},{"groupId":"EG001","numAffected":2,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":5,"numAtRisk":268}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":2,"numAtRisk":92},{"groupId":"EG003","numAffected":5,"numAtRisk":268}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":87},{"groupId":"EG001","numAffected":2,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":5,"numAtRisk":268}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":6,"numAtRisk":268}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":87},{"groupId":"EG001","numAffected":11,"numAtRisk":89},{"groupId":"EG002","numAffected":12,"numAtRisk":92},{"groupId":"EG003","numAffected":30,"numAtRisk":268}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":87},{"groupId":"EG001","numAffected":1,"numAtRisk":89},{"groupId":"EG002","numAffected":1,"numAtRisk":92},{"groupId":"EG003","numAffected":5,"numAtRisk":268}]},{"term":"Increased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":87},{"groupId":"EG001","numAffected":2,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":6,"numAtRisk":268}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":87},{"groupId":"EG001","numAffected":2,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":7,"numAtRisk":268}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":87},{"groupId":"EG001","numAffected":0,"numAtRisk":89},{"groupId":"EG002","numAffected":2,"numAtRisk":92},{"groupId":"EG003","numAffected":6,"numAtRisk":268}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":87},{"groupId":"EG001","numAffected":5,"numAtRisk":89},{"groupId":"EG002","numAffected":8,"numAtRisk":92},{"groupId":"EG003","numAffected":18,"numAtRisk":268}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":87},{"groupId":"EG001","numAffected":16,"numAtRisk":89},{"groupId":"EG002","numAffected":19,"numAtRisk":92},{"groupId":"EG003","numAffected":47,"numAtRisk":268}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":87},{"groupId":"EG001","numAffected":5,"numAtRisk":89},{"groupId":"EG002","numAffected":0,"numAtRisk":92},{"groupId":"EG003","numAffected":7,"numAtRisk":268}]},{"term":"Irritability","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":2,"numAtRisk":92},{"groupId":"EG003","numAffected":8,"numAtRisk":268}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":87},{"groupId":"EG001","numAffected":0,"numAtRisk":89},{"groupId":"EG002","numAffected":5,"numAtRisk":92},{"groupId":"EG003","numAffected":6,"numAtRisk":268}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":87},{"groupId":"EG001","numAffected":1,"numAtRisk":89},{"groupId":"EG002","numAffected":4,"numAtRisk":92},{"groupId":"EG003","numAffected":11,"numAtRisk":268}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":1,"numAtRisk":92},{"groupId":"EG003","numAffected":5,"numAtRisk":268}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":87},{"groupId":"EG001","numAffected":3,"numAtRisk":89},{"groupId":"EG002","numAffected":1,"numAtRisk":92},{"groupId":"EG003","numAffected":10,"numAtRisk":268}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":87},{"groupId":"EG001","numAffected":0,"numAtRisk":89},{"groupId":"EG002","numAffected":3,"numAtRisk":92},{"groupId":"EG003","numAffected":3,"numAtRisk":268}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The PI must remove any previously undisclosed Confidential Information (other than the Study results themselves) before public release."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003865","term":"Depressive Disorder, Major"},{"id":"D003863","term":"Depression"}],"ancestors":[{"id":"D003866","term":"Depressive Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"},{"id":"D001526","term":"Behavioral Symptoms"},{"id":"D001519","term":"Behavior"}]}},"hasResults":true}